Reneuron Regulatory News (RENE)

For Immediate Release 17 January 2012

ReNeuron Group plc

("ReNeuron" or "the Company")

ReNeuron confirms webcast and content of its Stem Cell Technical Seminar

Date: 17 January 2012

ReNeuron Group plc (AIM: RENE), a leading, UK-based stem cell company, is pleased to announce that it will host a live and recorded webcast of the previously announced Stem Cell Technical Seminar for analysts, investors and media to be held today, commencing at 10:00am (GMT).

Webcast Details

Running in parallel with the Stem Cell Technical Seminar will be a live webcast. Please log on 10 minutes before the start of the webcast at (10:00am GMT). The webcast log on address is:

http://mediaserve.buchanan.uk.com/2012/reneuron170112/registration.asp

A recording of the webcast will also be made available on Buchanan's and ReNeuron's websites following the seminar. Details are as follows: For Buchanan: www.buchanan.uk.com. For ReNeuron: www.reneuron.com

ReNeuron's Stroke Clinical Trial

The seminar will include a progress report on the PISCES clinical trial of ReNeuron's ReN001 stem cell therapy for disabled stroke patients.The Company last provided an update on the study on 28 November, 2011. Since then, the second, fourth and fifth patients treated in the study have reached their twelve, three and one month follow-up points, respectively. There continue to be no cell-related adverse events reported in any of the patients treated to date and neurological and other safety assessments continue to show no deterioration in the health of any of the patients as a result of the ReN001 treatment.

The study's Principal Investigator, Glasgow University's ProfessorKeith Muir, presented a progress report with the PISCES clinical trialat the Stroke Association's 6th UK Stroke Forum Conference in Glasgow inlate November 2011. Professor Muir's presentation today will incorporate the information given in that earlier progress report and will take into account the further follow-up points reached since his last progress report, as detailed above.

A detailed agenda for the seminar is shown below.

ReNeuron Stem CellTechnical Seminar: 17 January 2012

PRELIMINARY AGENDA

10.00-10.15 Registration and coffee

10.15-10.25 Introduction

Michael Hunt - Chief Executive Officer, ReNeuron

10.25-10.35 Stem cells - their potential as a new therapeutic paradigm

Colin Blakemore FMedSciFRS - Professor of Neuroscience, Department of Physiology, Anatomy and Genetics, University of Oxford

10.35-10.45 Overview and advantages of ReNeuron's stem cell technologies

Dr John Sinden - Chief Scientific Officer, ReNeuron

10.45-11.05 The PISCES clinical trial with ReN001 for stroke - a progress report

Keith Muir - SINAPSE Professor of Clinical Imaging and Consultant Neurologist, Institute of Neuroscience and Psychology, University of Glasgow

11.05-11.15 Coffee break

11.15-11.30 Clinical development of ReN001 and ReNeuron's other cell-based therapies - opportunities and challenges

Dr Mike McDonald - Clinical Development Consultant to ReNeuron

11.30-11.45 Manufacturing and scale-up of ReNeuron's cell-based therapies

Dr Kenny Pollock - Head of Cell Development, ReNeuron

11.45-12.00 ReN009 for critical limb ischaemia - progress to date and future plans

Dr Paul Stroemer - Programme Manager &Head of Pre-clinical Research, ReNeuron

12.00-12.15 ReN003 for retinitis pigmentosa - progress to date and future plans

Dr Sara Patel - Programme Manager & Head of Toxicology, ReNeuron

12.15-12.30 Q&A

12.30-13.30 Buffet lunch

- Ends -

Enquiries:

Michael Hunt, Chief Executive Officer - ReNeuron +44 (0) 1483 302560

Dr John Sinden, Chief Scientific Officer - ReNeuron

Lisa Baderoon, Mark Court, Isabel Podda +44 (0) 20 7466 5000

Buchanan Communications

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.